Find out how leukemia cells affect the treatment of pediatric patients with B-cell acute lymphoblastic leukemia and acute ...

Hematopoietic stem cells (HSCs) are the fundamental building blocks of our circulatory system, giving rise to all blood cell ...

CAR architecture has evolved through four generations. The first relied solely on CD3ζ and lacked potency. Second-generation receptors added either ...

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

Chimeric antigen receptor T cell therapy has reshaped expectations for treating hematological malignancies and is now reaching toward autoimmune ...

A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a cancer ...

Caribou Biosciences' allogeneic CAR T-cell therapies show promising early efficacy and safety, but require clinical ...

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Study shows potential of NanoCell Therapeutics' NCtx platform, and durable CAR-T therapy without ex vivo manufacturing First indication of stable, functional CAR-T cell generation in vivo using ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than ...

The dual-targeting approach to both CD20 and CD19 antigens aims to enhance therapeutic efficacy and reduce the likelihood of antigen escape, a common mechanism of resistance in B-cell malignancies.

JNJ-4496, formerly known as C-CAR039, is a dual-targeting CAR T designed to bind to both CD19 and CD20 antigens — two cell surface proteins commonly expressed on malignant B-cells. This design, ...